Aditxt files amendment with Evofem Q1 results; merger deadline extended to Sep 30, 2025

Aditxt, Inc.

Evofem Q1 2025 product sales net $845K, down 77% YoY from $3.6M; net income of $956K vs net loss $4.8M.
Fifth Amendment to merger agreement moves required close to Sep 30, 2025; Aditxt to invest $1.5M in April 2025.
Aditxt terminated Appili Therapeutics arrangement agreement effective May 31, 2025; removed from pro forma.
Evofem had working capital deficit of $65M, accumulated deficit $896.7M, and substantial doubt as going concern.
Evofem common stock moved from OTCQB to OTC Pink in April 2025 after failing minimum bid price compliance.

item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.